실적분석 2026년 8월 20일

NovaBridge Bio ($NBP) 2026 Q2 Earnings Analysis — Zero Revenue in H1, Wider Loss, Modest After-Hours Decline on Cash Runway

Earnings Scorecard

Revenue: $0 (no product revenue; estimate was $0) — in line with consensus

EPS (earnings per share): Pending confirmation

Guidance: Not provided (no revenue or EPS outlook)

Stock reaction: -2.53% after hours ($1.93) — as of 21:09 KST on 08-20

Positives

Cash runway: $216 million in cash and equivalents as of June 30, 2026, with no debt

Givastomig: Targeting Phase 3 initiation by year-end; pursuing accelerated approval eligibility

Vias101: Plans to begin Phase 2b in the second half; Phase 1 completed

Clinical candidate timelines have become more defined, and the company said its current cash is sufficient to reach the Givastomig Phase 3 interim analysis in 2028. The strategy is to expand the pipeline across two pillars: gastric cancer and retinal disease.

Negatives

Detailed P&L: Income-statement figures, including net loss attributable to shareholders, remain pending official confirmation

Cost detail: Line-item operating expenses such as R&D and G&A are pending official confirmation

Revenue gap: Product revenue of $0; pre-approval clinical and funding risks persist

Clinical and operating cost burdens may continue in the pre-approval stage.

What Management Said

The CEO explained that the strategy of selecting promising therapies emerging from across regions and developing them efficiently is reflected in the progress of Givastomig and Vias101. No specific revenue or profit figures were disclosed, with emphasis placed on the cash runway supporting the company through key clinical milestones.

Market Reaction and What to Watch

As a clinical-stage company, there is no revenue surprise, and detailed P&L and cost figures remain pending official confirmation, leaving room for interpretation. Pipeline timelines were largely already known, so the price rebound was not significant.

Check whether the Givastomig Phase 1b dose-expansion data presented at the European Oncology Congress in October meet expectations.

Monitor the start of Givastomig Phase 3 around year-end and the launch of the Vias101 Phase 2b in the second half.

Watch whether partnership and funding discussions translate into actual agreements.